Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-4157 Alone and in Combination in Participants With Solid Tumors
NCT03313778Phase 1Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Aug 2017
- Primary completion
- Nov 2027
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 4
01
Overview
Phase 1, open-label trial of intismeran autogene in solid tumor, pancreatic ductal adenocarcinoma (PDAC), melanoma and 3 more (8 arms), sponsored by Moderna Inc. Primary endpoint: Number of Participants with Adverse Events. Started Aug 2017; status: active, not recruiting.
02
Drugs
intismeran autogene
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)melanomanon-small cell lung cancer (NSCLC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT03313778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03313778.